Booth 502
Date
September 30 - October 2, 2025
Phenomenex develops innovative chromatographic solutions to support the evolving needs of biopharmaceutical chromatographic method development. Our advanced technologies are designed to deliver accurate, reliable results for the industry's complex analytical challenges. Meet our team to explore how we can address your needs.
Explore Products and Applications from Phenomenex
Stay tuned for more talks and posters.
| Time | Type | Description | Room / Location | Presenter |
| 18:10 | POSTERS | Determination of sgRNA and mRNA Sequence Identity by Ion-Pair Reversed-Phase Chromatography and High-Resolution Tandem Mass Spectrometry Poster: 142
A sgRNA targeting the BRAC1 and Cas9-mRNA were used as model systems and enzymatically digested to be analyzed by IP-RP chromatography coupled with HRMS. This workflow shows full sequence identification and chromatographic resolution of impurities and Phosphorothioate (PS) diastereomers of sgRNA. Similarly, Cas9-mRNA sequence identification was achieved in 5’-UTR / 3’-UTR regions, 5’Cap, and Poly-A tail, all while revealing partially capped species, deletions, and Poly-A heterogeneity.
Phenomenex | Poster Area | Tran N. Pham |
| 18:10 | POSTERS | Size Exclusion Chromatographic (SEC) Method for Oligonucleotides Using Heated Columns Poster: 144
A prototype size exclusion chromatographic (SEC) column is described and tested for various AAV serotypes. Its pore size, inert particle chemistry, particle size and bio-inert hardware were found to enable highly reproducible separation and recoveries of the AAV monomer and its aggregates and impurities even amongst batches of columns. The percentage relative standard deviations of the peak area, retention time, and % monomer were all < 1%. This performance not only enables the determination of the critical quality attributes in drug substances and drug products but also allows the use of SEC to develop ion exchange and reverse phase LC methods.
Phenomenex | Poster Area | Crystal Holt |
| 18:10 | POSTERS | Native RPLC-HRMS Method Development Approach for the Rapid Characterization of Antibody Drug Conjugates Poster: 143
A method development approach for native RPLC-HRMS allowing rapid, comprehensive characterization, including average DAR value, of a variety of intact ADCs using a new set of RPLC columns will be described. The effect of sorbent polarity and hydrophobicity on the retention and selectivity of individual DAR species in several commercial ADC drugs will be demonstrated.Optimized chromatographic separation and MS identification of all DAR species, including positional isomers, of several ADCs are shown.
Phenomenex | Poster Area | Dr. Juergen Niesser, Ph.D |
| 18:10 | POSTERS | Suitable Size Exclusion Column for Efficient Adeno-Associated Virus Aggregate Analysis Poster: 145
Biozen™ dSEC-7, a chromatographic (SEC) column, is described and tested for various AAV serotype aggregates. Its 700 Å pore size, inert particle chemistry, and applicable particle size(s) are found to enable highly reproducible baseline separation and recoveries of the AAV monomer and its aggregates, even amongst batches of columns, within 10 minutes. The percentage relative standard deviations of the peak area, retention time, and % monomer were all < 1 % with as little as 0.5 µL of sample. This performance enables faster and more accurate determination of AAV aggregates, a critical quality attribute (CQA) in drug substances and drug products, without compromising data quality.
Phenomenex | Poster Area | Dr. Dirk Hansen, Ph.D |
Phenomenex
We see a way to improve the recovery and consistency of your biotherapeutic sample by more than 80%, significantly accelerating the drug development process
Phenomenex
Reversed-Phase Selectivity for Peptide Mapping
Phenomenex
sgRNA and Cas9 mRNA Characterization by Ion Pair-Reversed Phase Liquid Chromatography Coupled to HRMS
Phenomenex
Utilizing Biozen™ NativeRP-5 Column for Rapid RPLC-HRMS Separation and Identification of Native, Intact Antibody Drug Conjugate Species
Phenomenex
Towards an Enhanced Solid Phase Extraction Workflow for Modern Oligonucleotide Therapeutic Modalities